Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: COMPARISON of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology

Neurobiology of Disease

Volumn 74, Issue , 2015, Pages 158-166

  Öz, Gülin ^a   Kittelson, Emily ^a   Demirgöz, Döne ^a,c   Rainwater, Orion ^a   Eberly, Lynn E ^b   Orr, Harry T ^a   Clark, H Brent ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c 3M COMPANY   (United States)

Author keywords

Histology; Magnetic resonance spectroscopy; Outcome measures; Receiver operating characteristic analysis; Rotarod; Spinocerebellar ataxia; Transgenic

Indexed keywords

ATAXIN 1; DOXYCYCLINE; INOSITOL; LACTIC ACID; N ACETYLASPARTIC ACID; TAURINE; ASPARTIC ACID; ATXN1 PROTEIN, HUMAN; N-ACETYLASPARTATE;

ACCURACY; ANALYTICAL PARAMETERS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; GENE EXPRESSION; GENE REPRESSION; HISTOPATHOLOGY; INTERMETHOD COMPARISON; LATENT PERIOD; MALE; MOLECULAR LAYER THICKNESS; MOUSE; N ACETYLASPARTATE TO MYOINOSITOL RATIO; NERVE DEGENERATION; NEUROCHEMISTRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PURKINJE CELL; RECEIVER OPERATING CHARACTERISTIC; ROTAROD TEST; SENSITIVITY AND SPECIFICITY; SPINOCEREBELLAR ATAXIA 1; SPINOCEREBELLAR DEGENERATION; TRANSGENE; TREND STUDY; ANALOGS AND DERIVATIVES; ANIMAL; CEREBELLUM; COMPARATIVE STUDY; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SPINOCEREBELLAR ATAXIAS; TRANSGENIC MOUSE;

ANIMALS; AREA UNDER CURVE; ASPARTIC ACID; ATAXIN-1; CEREBELLUM; DOXYCYCLINE; GENE EXPRESSION; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE, TRANSGENIC; MOTOR ACTIVITY; POLYMERASE CHAIN REACTION; RECOVERY OF FUNCTION; ROC CURVE; ROTAROD PERFORMANCE TEST; SENSITIVITY AND SPECIFICITY; SPINOCEREBELLAR ATAXIAS;

EID: 84919794317     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.11.011     Document Type: Article

References (29)

1. Burright E.N., Clark H.B., Servadio A., Matilla T., Feddersen R.M., Yunis W.S., Duvick L.A., Zoghbi H.Y., Orr H.T. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 1995, 82:937-948.
2. Clark H.B., Burright E.N., Yunis W.S., Larson S., Wilcox C., Hartman B., Matilla A., Zoghbi H.Y., Orr H.T. Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J. Neurosci. 1997, 17:7385-7395.
3. Deelchand D.K., Adanyeguh I.M., Emir U.E., Nguyen T.M., Valabregue R., Henry P.G., Mochel F., Öz G. Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single voxel MRS at 3T. Magn. Reson. Med. 2014, 10.1002/mrm.25295.
4. Deelchand D.K., Emir U.E., Hutter D., Gomez C.M., Eberly L.E., Bushara K.O., Öz G. High field MRS is more sensitive to progression of neurodegeneration than clinical decline in spinocerebellar ataxia type 1 (SCA1). Proc. Int. Soc. Magn. Reson. Med. 2014, 22:64. [Milan, Italy].
5. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
6. Emir U.E., Brent Clark H., Vollmers M.L., Eberly L.E., Öz G. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J. Neurochem. 2013, 127:660-668.
7. Emir U.E., Hutter D., Bushara K.O., Gomez C.M., Eberly L.E., Öz G. MRS biomarkers of neurodegeneration in spinocerebellar ataxia type 1 (SCA1): current and future potential. 20th Scientific Meeting of the ISMRM 2012, 1802. [Melbourne, Australia].
8. Garwood M., DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J. Magn. Reson. 2001, 153:155-177.
9. Gruetter R., Tkáč I. Field mapping without reference scan using asymmetric echo-planar techniques. Magn. Reson. Med. 2000, 43:319-323.
10. Hennig J., Nauerth A., Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med. 1986, 3:823-833.
11. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 6:65-70.
12. Ifediba M.A., Moore A. In vivo imaging of the systemic delivery of small interfering RNA. Wiley Interdiscip. Rev. Nanomed Nanobiotechnol. 2012, 4:428-437.
13. Keiser M.S., Boudreau R.L., Davidson B.L. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol. Ther. 2014, 22:588-595.
14. Keiser M.S., Geoghegan J.C., Boudreau R.L., Lennox K.A., Davidson B.L. RNAi or overexpression: alternative therapies for spinocerebellar ataxia type 1. Neurobiol. Dis. 2013, 56:6-13.
15. Kordasiewicz H.B., Stanek L.M., Wancewicz E.V., Mazur C., McAlonis M.M., Pytel K.A., Artates J.W., Weiss A., Cheng S.H., Shihabuddin L.S., Hung G., Bennett C.F., Cleveland D.W. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012, 74:1031-1044.
16. Koretsky A.P. Is there a path beyond BOLD? Molecular imaging of brain function. Neuroimage 2012, 62:1208-1215.
17. Nagae-Poetscher L.M., Bonekamp D., Barker P.B., Brant L.J., Kaufmann W.E., Horska A. Asymmetry and gender effect in functionally lateralized cortical regions: a proton MRS imaging study. J. Magn. Reson. Imaging 2004, 19:27-33.
18. Öz G., Hutter D., Tkáč I., Clark H.B., Gross M.D., Jiang H., Eberly L.E., Bushara K.O., Gomez C.M. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov. Disord. 2010, 25:1253-1261.
19. Öz G., Iltis I., Hutter D., Thomas W., Bushara K.O., Gomez C.M. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum 2011, 10:208-217.
20. Öz G., Nelson C.D., Koski D.M., Henry P.G., Marjanska M., Deelchand D.K., Shanley R., Eberly L.E., Orr H.T., Clark H.B. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 2010, 30:3831-3838.
21. Öz G., Vollmers M.L., Nelson C.D., Shanley R., Eberly L.E., Orr H.T., Clark H.B. In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp. Neurol. 2011, 232:290-298.
22. Pouwels P.J., Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn. Reson. Med. 1998, 39:53-60.
23. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30:672-679.
24. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science 2002, 296:1991-1995.
25. 1H NMR spectroscopy of rat brain at 1ms echo time. Magn. Reson. Med. 1999, 41:649-656.
26. Vandsburger M.H., Radoul M., Cohen B., Neeman M. MRI reporter genes: applications for imaging of cell survival, proliferation, migration and differentiation. NMR Biomed. 2013, 26:872-884.
27. Xia H., Mao Q., Eliason S.L., Harper S.Q., Martins I.H., Orr H.T., Paulson H.L., Yang L., Kotin R.M., Davidson B.L. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 2004, 10:816-820.
28. Zoghbi H.Y., Orr H.T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 2009, 284:7425-7429.
29. Zu T., Duvick L.A., Kaytor M.D., Berlinger M.S., Zoghbi H.Y., Clark H.B., Orr H.T. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 2004, 24:8853-8861.